Join the Myelodysplastic Syndrome group to help and get support from people like you.
Myelodysplastic Syndrome News
Related terms: MDS
FDA Approves Rytelo (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
FOSTER CITY, Calif.--(BUSINESS WIRE) June 6, 2024 – Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,...
Review Explores Cutaneous Manifestations of Myelodysplastic Syndrome
FRIDAY, April 19, 2024 – Cutaneous manifestations of myelodysplastic syndrome (MDS) are described in a perspective piece published in the April issue of Skin Health and Disease. Xiang Li Tan,...
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
WEDNESDAY, Feb. 21, 2024 – Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical hematopoietic stem cell transplantation...
Imetelstat Leads to Durable Red Blood Cell Transfusion Independence
TUESDAY, Jan. 9, 2024 – For heavily transfused patients with lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs),...
Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation Fifth approved indication for Tibsovo solidifies Servier's leadership in mutant IDH...
Tolerable Treatments Lacking for Higher-Risk Myelodysplastic Syndromes
FRIDAY, Oct. 20, 2023 – There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a...
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
PRINCETON, N.J.--(BUSINESS WIRE) August 28, 2023-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the...
Risks for MDS/Leukemia Increased for Survivors of Common Lymphoid Neoplasms
THURSDAY, Aug. 17, 2023 – Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been...
Precursor to Blood Cancer Is 'Tricky to Diagnose,' Study Shows
WEDNESDAY, Aug. 9, 2023 – New research shows hard-to-diagnose blood disorders called myelodysplastic syndromes/neoplasms (MDS) are often misdiagnosed and a second opinion may be needed. The...
FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)
Pleasanton, CA, Princeton, NJ, and Tokyo, Japan, July 7, 2020. Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug...
FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine)...
Ask a question
To post your own question to this support group, sign in or create an account.